A meta-analysis of 29 RCTs with 37,348 non-diabetic overweight/obese participants found GLP-1-based therapies reduced total cardiovascular events by 19%, heart attacks by 28%, and all-cause mortality by 19%.
28% fewer heart attacksGLP-1-based therapies reduced myocardial infarction risk by 28% (RR 0.72) in non-diabetic overweight/obese adults across 29 randomized controlled trials — the strongest cardiovascular signal in this population to date.
What the researchers found
Pooled analysis of 29 RCTs (37,348 participants, 9 GLP-1RA-based drugs) in non-diabetic overweight/obese adults found:
**Cardiovascular Outcomes (vs. placebo):**
- Total cardiovascular events: RR 0.81 (95% CI: 0.76-0.87) — 19% reduction
- Major adverse cardiovascular events (MACE): RR 0.80 (0.72-0.89) — 20% reduction
- Myocardial infarction: RR 0.72 (0.61-0.85) — 28% reduction
- All-cause mortality: RR 0.81 (0.71-0.93) — 19% reduction
- Cardiovascular death: no significant difference
- Stroke: no significant difference
**Best-in-class for cardiometabolic parameters:**
- Systolic blood pressure: Orforglipron (-7.10 mmHg)
- BMI reduction: Tirzepatide (-6.50 kg/m²)
- HbA1c reduction: Tirzepatide (-0.39%)
- Lipid profiles: Retatrutide (most effective)
- C-reactive protein: Semaglutide (-1.20 mg/dL)
Why it matters
Until recently, the cardiovascular benefits of GLP-1 medications were only proven in people with diabetes. This meta-analysis demonstrates that these drugs also protect the heart in non-diabetic obese individuals — expanding the potential beneficiaries to hundreds of millions of people worldwide. The head-to-head drug comparisons also provide practical guidance for clinicians choosing between different GLP-1 medications based on each patient's specific risk profile.
How the study worked
Systematic meta-analysis of RCTs searched across PubMed, Embase, Cochrane, and Web of Science (through June 2024). Inclusion criteria: randomized controlled trials in non-diabetic adults with overweight/obesity comparing GLP-1RA-based therapies to placebo, reporting cardiovascular events and metabolic parameters. 29 RCTs with 9 different drugs and 37,348 participants were included. Relative risks and mean differences were calculated with 95% confidence intervals.
What this study cannot tell us
While the overall sample is large (37,348), the cardiovascular event data are likely driven primarily by a few large trials (particularly SELECT). Some of the 9 drugs included had limited trial data. Stroke and cardiovascular death did not show significant reductions, which may reflect insufficient power or a true lack of effect. Follow-up durations varied across trials. The analysis includes both single GLP-1 agonists and dual/triple agonists, which may have different mechanisms. Publication bias was not explicitly addressed in the abstract.
How to read the evidence
This is a comprehensive meta-analysis of 29 randomized controlled trials — the gold standard of evidence. The large sample (37,348), consistent results across multiple cardiovascular outcomes, and comparison of 9 different drugs provide strong, high-quality evidence for the cardiovascular benefits of GLP-1-based therapies in non-diabetic obesity.
When this study was published
Published in 2025 with data through June 2024, this is one of the most current and comprehensive meta-analyses on GLP-1 medications' cardiovascular effects in non-diabetic populations.
The bigger picture
This meta-analysis represents a landmark in the GLP-1 field by definitively establishing cardiovascular protection in non-diabetic obesity. Combined with the SELECT trial (semaglutide in non-diabetic obesity) and SURMOUNT trials (tirzepatide), these data are reshaping obesity from a cosmetic concern into a cardiovascular disease requiring pharmaceutical treatment. The drug-specific comparison data also foreshadow a future of personalized GLP-1 therapy, where clinicians select specific agents based on each patient's dominant cardiovascular risk factors.
Questions still open
- Will longer-term follow-up reveal cardiovascular death and stroke reductions that this analysis lacked power to detect?
- Should specific GLP-1 medications be chosen based on individual cardiovascular risk profiles (e.g., semaglutide for high CRP, orforglipron for hypertension)?
- Do the cardiovascular benefits persist after stopping GLP-1 therapy, or are they dependent on continued treatment?
Common questions
Do GLP-1 medications protect the heart even if you don't have diabetes?
Which GLP-1 medication is best for heart health?
Read the original research
Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Journal of diabetes, 17(4), e70082
Citation
Yin, Yue; Zhang, Minghan; Cao, Qiuyu; Lin, Lin; Lu, Jieli; Bi, Yufang; Chen, Yuhong. (2025). Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.. Journal of diabetes, 17(4), e70082. https://doi.org/10.1111/1753-0407.70082